AI Stock Finder
Loading...
Skip to main content
Stock comparison · Signal date 2026-11-06

BRVE vs RARE: stock comparison and AI forecast

Braveheart Bio, Inc. (BRVE) and Ultragenyx Pharmaceutical Inc. (RARE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Pharmaceutical Preparations

BRVE Braveheart Bio, Inc.

Market Cap
$1.52B
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Nasdaq · Pharmaceutical Preparations

RARE Ultragenyx Pharmaceutical Inc.

Market Cap
$1.52B
P/E Ratio
–
Size
small-cap
AI Forecast
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

BRVE · RARE

Key facts

  • BRVE and RARE have similar market capitalizations ($1.52B and $1.52B).
  • Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricBRVERARE
Market Cap$1.52B$1.52B
EPS–$-5.18
Revenue/Share–$6.03
FCF/Share–$-4.48

Profitability & Margins

MetricBRVERARE
ROA–-44.1%
ROIC–-58.6%
Operating Margin–-78.6%
Net Margin–-88.1%
EBT Margin–-89.1%
Tax Rate–1.2%

Financial Health

MetricBRVERARE
Current Ratio13.63x1.40x
Quick Ratio–1.25x
Interest Coverage–-32.5x
Working Capital$114M$155M

Cash Flow

MetricBRVERARE
Operating Cash Flow–-$437M
Free Cash Flow–-$442M
Capital Spending–-$5M
FCF/Sales–-74.3%
CapEx/Sales–0.8%

Operational Efficiency

MetricBRVERARE
Asset Turnover–0.50x
Receivables Turnover–3.6x
Fixed Assets Turnover–2.6x
Days Sales Outstanding–102 days

Income Statement

MetricBRVERARE
Total Revenue–$594M
Operating Income–-$467M
Net Income–-$524M
R&D Expense–$711M
SG&A Expense–$361M

Dividend & Shareholder Information

MetricBRVERARE
Shares Outstanding82M99M
FAQ

BRVE vs RARE: stock comparison and AI forecast

Which is bigger, BRVE or RARE?

BRVE and RARE have similar market capitalizations ($1.52B and $1.52B).

Which one does Intratio's AI model rank higher, BRVE or RARE?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.